Novo Nordisk (NVO) Gets Positive CHMP Opinion for Insulin Icodec

Novo Nordisk (NVO) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) adopted a positive opinion, recommending marketing authorization for once-weekly basal insulin icodec for the treatment of diabetes in adults. The basal insulin has been recommended under the brand name Awiqli.The positive CHMP opinion is based on results from the phase IIIa ONWARDS program. The program comprised six phase IIIa global clinical trials, which investigated the efficacy and ...